{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:25:35Z","timestamp":1783772735470,"version":"3.55.0"},"reference-count":183,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Off-label treatment is the use of a drug approved for marketing, outside the registration in terms of indication, age group, dose or route of administration. Despite the constant appearance of new preparations on the market, treatment outside the SmPCs guidelines is a current clinical problem. It is believed that it is based on the needs of patients unmet by classical therapy methods. This work focuses on off-label treatment in inflammatory dermatoses such as atopic dermatitis, psoriasis, acne vulgaris and rosacea. Publications on this subject, available on PubMed, Google Scholar and the Cochrane Library, were analyzed in the form of a review, taking into account the mechanisms of action, efficacy and safety of preparations. Based on the literature analysis, it can be concluded that the use of drugs outside the SmPC indications is a common situation in dermatology. However, it is difficult to determine its exact frequency\u2014there is a lack of data on the prevalence of off-label appliances in inflammatory dermatoses from a European perspective. Publications demonstrate varying effectiveness and safety of this form of therapy, depending on the specific preparation. Off-label treatment in dermatology remains an important and current clinical issue that should be explored in further research.<\/jats:p>","DOI":"10.3390\/jcm14072376","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:50:16Z","timestamp":1743389416000},"page":"2376","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Off-Label Treatment in Inflammatory Skin Diseases\u2014European Point of View"],"prefix":"10.3390","volume":"14","author":[{"given":"Julia","family":"Sternicka","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Medical University of Gda\u0144sk, University Clinical Centre, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4768-1387","authenticated-orcid":false,"given":"Roman J.","family":"Nowicki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Medical University of Gda\u0144sk, University Clinical Centre, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Bieniaszewski","sequence":"additional","affiliation":[{"name":"Clinical Physiology Unit, Medical Simulation Centre, Medical University of Gda\u0144sk, 80-204 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6089-8030","authenticated-orcid":false,"given":"Dorota","family":"Purzycka-Bohdan","sequence":"additional","affiliation":[{"name":"Clinical Physiology Unit, Medical Simulation Centre, Medical University of Gda\u0144sk, 80-204 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jclinepi.2017.11.006","article-title":"Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials","volume":"94","author":"Ladanie","year":"2018","journal-title":"J. Clin. Epidemiol."},{"key":"ref_2","first-page":"225","article-title":"Off-label prescriptions: How to identify them, frame them, announce them and monitor them in practice?","volume":"68","author":"Billon","year":"2013","journal-title":"Therapie"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rusz, C.M., \u0150sz, B.E., J\u00eetc\u0103, G., Miklos, A., B\u0103tr\u00eenu, M.G., and Imre, S. (2021). Off-label medication: From a simple concept to complex practical aspects. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph181910447"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1111\/bcp.13394","article-title":"Unlicensed and off-label uses of medicines: Definitions and clarification ofterminology","volume":"83","author":"Aronson","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2147\/TCRM.S40232","article-title":"Ethical and legal framework and regulation for off-label use: European perspective","volume":"10","author":"Lenk","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/ijd.14222","article-title":"Controversies in off-label prescriptions in dermatology: The perspective of the patient, the physician, and the pharmaceutical companies","volume":"58","author":"Litewka","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1542\/peds.2013-4060","article-title":"Off-label use of drugs in children","volume":"133","author":"Frattarelli","year":"2014","journal-title":"Pediatrics"},{"key":"ref_8","first-page":"11","article-title":"Off-label medication use","volume":"50","author":"Howland","year":"2012","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4103\/ijo.IJO_586_17","article-title":"A tale of two drugs: Off and on-label","volume":"65","author":"Narayanan","year":"2017","journal-title":"Indian J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/clpt.2012.24","article-title":"Monitoring the safety of medicines used off-label","volume":"91","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","first-page":"53","article-title":"The law and practice of off-label prescribing and physician promotion","volume":"49","author":"Syed","year":"2021","journal-title":"J. Am. Acad. Psychiatry Law"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12519-018-0186-y","article-title":"Two decades of off-label prescribing in children: A literature review","volume":"14","author":"Balan","year":"2018","journal-title":"World J. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/clpt.2012.37","article-title":"The many sides of off-label prescribing","volume":"91","author":"Epstein","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.31128\/AJGP-08-20-5591","article-title":"Off-label medicine use: Ethics, practice and future directions","volume":"50","author":"Bell","year":"2021","journal-title":"Aust. J. Gen. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2174\/138945012800675759","article-title":"Off-label drug use in pediatrics: A worldwide problem","volume":"13","author":"Lenk","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-014-1768-9","article-title":"Use of off-label and unlicensed drugs in hospitalized pediatric patients: A systematic review","volume":"71","author":"Rodrigues","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"The Lancet (2019). Prescribing off-label drugs for children: When will it change?. Lancet, 394, 1114.","DOI":"10.1016\/S0140-6736(19)32212-3"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdz445","article-title":"When is off-label off-road?","volume":"30","author":"Cherny","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1177\/1203475419857668","article-title":"Off-label use of topical calcineurin inhibitors in dermatologic disorders","volume":"23","author":"Guenther","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jaad.2019.07.038","article-title":"The frequency of off-label prescribing in the treatment of dermatologic diseases during 2006\u20132015","volume":"82","author":"Chu","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1067\/mjd.2002.120469","article-title":"Off-label prescribing in the treatment of dermatologic disease","volume":"47","author":"Sugarman","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","first-page":"429","article-title":"Off-label drugs in childhood psoriasis","volume":"147","author":"Corgibet","year":"2020","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/all.12498","article-title":"Off-label prescriptions for atopic dermatitis in Europe","volume":"70","author":"Bieber","year":"2015","journal-title":"Allergy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00128071-200809040-00003","article-title":"Immunology and treatment of atopic dermatitis","volume":"9","author":"Spergel","year":"2008","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sroka-Tomaszewska, J., and Trzeciak, M. (2021). Molecular mechanisms of atopic dermatitis pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084130"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","article-title":"Atopic dermatitis: Pathophysiology","volume":"1027","author":"Boothe","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2133.2007.08412.x","article-title":"Diagnostic criteria for atopic dermatitis: A systematic review","volume":"158","author":"Brenninkmeijer","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000247298","article-title":"Severity scoring of atopic dermatitis: The SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis","volume":"186","author":"Schallreuter","year":"1993","journal-title":"Dermatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2165\/00128071-200304110-00005","article-title":"Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders","volume":"4","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Afshari, M., Kolackova, M., Rosecka, M., \u010celakovsk\u00e1, J., and Krejsek, J. (2024). Unraveling the skin: A comprehensive review of atopic dermatitis, current understanding, and approaches. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1361005"},{"key":"ref_32","first-page":"145","article-title":"Clinical practice guidelines for the diagnosis and management of atopic dermatitis","volume":"39","author":"Kulthanan","year":"2021","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"T784","DOI":"10.1016\/j.ad.2023.06.012","article-title":"Long-term safety profile and off-label use of JAK inhibitors in dermatological disorders","volume":"114","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: Part I\u2014Systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jid.2023.10.019","article-title":"Genetic and Immunological Pathogenesis of Atopic Dermatitis","volume":"144","author":"Weidinger","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1159\/000514535","article-title":"Biological Therapies for Atopic Dermatitis: A Systematic Review","volume":"237","author":"Zhou","year":"2021","journal-title":"Dermatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"adv11937","DOI":"10.2340\/actadv.v102.11937","article-title":"Off-label Prescription in Paediatric Dermatology: A Retrospective Observational Study in a Tertiary Hospital","volume":"103","author":"Batalla","year":"2023","journal-title":"Acta Derm. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5114\/ada.2022.119967","article-title":"Off-label Medications in the Treatment of Hospitalized Children with Atopic Dermatitis","volume":"40","author":"Narbutt","year":"2023","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.det.2017.02.007","article-title":"Long-Term Treatment of Atopic Dermatitis","volume":"35","author":"Prezzano","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/1203475419847950","article-title":"Off-label Uses of Topical Pimecrolimus","volume":"23","author":"Ladda","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1573396316999200820163434","article-title":"Brief Academic Review and Clinical Practice Guidelines for Pediatric Atopic Dermatitis","volume":"17","author":"Yang","year":"2021","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/ced.15024","article-title":"Safety of Tacrolimus 0.03% and 0.1% Ointments in Young Children with Atopic Dermatitis: A 36-Month Follow-up Study","volume":"47","author":"Salava","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Frantz, T., Wright, E.G., Balogh, E.A., Cline, A., Adler-Neal, A.L., and Feldman, S.R. (2019). Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis. Children, 6.","DOI":"10.3390\/children6110125"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1939-4551-7-4","article-title":"Off-Label Prescribing for Allergic Diseases in Children","volume":"7","author":"Silva","year":"2014","journal-title":"World Allergy Organ. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1542\/peds.2013-0931","article-title":"Off-Label Topical Calcineurin Inhibitor Use in Children","volume":"132","author":"Manthripragada","year":"2013","journal-title":"Pediatrics"},{"key":"ref_46","first-page":"307","article-title":"S3 Guideline Atopic Dermatitis: Part 2\u2014Systemic Treatment","volume":"22","author":"Werfel","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of Care for the Management of Atopic Dermatitis: Section 3. Management and Treatment with Phototherapy and Systemic Agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.iac.2020.06.004","article-title":"Biologics for Atopic Dermatitis","volume":"40","author":"Boguniewicz","year":"2020","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_49","first-page":"S33","article-title":"Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis\u2014A Review","volume":"13","author":"Cline","year":"2020","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_51","first-page":"105","article-title":"Cyclosporine in Dermatology","volume":"14","author":"Kutlubay","year":"2016","journal-title":"Skinmed"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1468-3083.2006.02023.x","article-title":"Cyclosporin in the treatment of patients with atopic eczema\u2014A systematic review and meta-analysis","volume":"21","author":"Schmitt","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","article-title":"Atopic Dermatitis","volume":"22","author":"Bieber","year":"2010","journal-title":"Ann. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of Care for the Management of Atopic Dermatitis in Adults with Phototherapy and Systemic Therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1080\/09546634.2021.1961999","article-title":"On Which Evidence Can We Rely When Prescribing Off-Label Methotrexate in Dermatological Practice? A Systematic Review with GRADE Approach","volume":"33","author":"Vermeulen","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clindermatol.2018.05.008","article-title":"Atopic Dermatitis Guidelines: Diagnosis, Systemic Therapy, and Adjunctive Care","volume":"36","author":"Sidbury","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/bjd\/ljad281","article-title":"Efficacy and Safety of Ciclosporin Versus Methotrexate in the Treatment of Severe Atopic Dermatitis in Children and Young People (TREAT): A Multicentre Parallel Group Assessor-Blinded Clinical Trial","volume":"189","author":"Flohr","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_58","unstructured":"(2025, February 05). Electronic Medicines Compendium. Available online: https:\/\/www.medicines.org.uk\/emc\/browse-ingredients."},{"key":"ref_59","unstructured":"(2025, February 05). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/homepage."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Barak Levitt, J.A., Alemi, S., Ollech, A., Reiss-Huss, S., Sah, M., Renert-Yuval, Y., Friedland, R., Greenberger, S., and Cohen Barak, E. (2023). Treatment with Methotrexate in Infants and Toddlers with Atopic Dermatitis: A Retrospective Multi-Center Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12165409"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/09546634.2019.1642996","article-title":"Mycophenolate Mofetil and Atopic Dermatitis: Systematic Review and Meta-Analysis","volume":"31","author":"Phan","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema Task Force 2020 Position Paper on Diagnosis and Treatment of Atopic Dermatitis in Adults and Children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/aap.2017.38.4054","article-title":"Atopic Dermatitis Treatment: Current State of the Art and Emerging Therapies","volume":"38","author":"Silverberg","year":"2017","journal-title":"Allergy Asthma Proc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/all.14631","article-title":"Systemic Treatments in the Management of Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"76","author":"Siegels","year":"2021","journal-title":"Allergy"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2019.10.010","article-title":"Off-Label Use of Dupilumab for Pediatric Patients with Atopic Dermatitis: A Multicenter Retrospective Review","volume":"82","author":"Igelman","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in Children Aged 6 Months to Younger Than 6 Years with Uncontrolled Atopic Dermatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0091-6749(05)80237-4","article-title":"The role of antihistamines in atopic dermatitis","volume":"86","author":"Hanifin","year":"1990","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/jdv.13060","article-title":"Systemic Antihistamines\u2014A Common Outside the Guidelines Therapeutic Strategy in Hand Eczema Management","volume":"30","author":"Reich","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s11096-018-0655-3","article-title":"A Systematic Review on the Off-Label Use of Montelukast in Atopic Dermatitis Treatment","volume":"40","author":"Chin","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4168\/aair.2016.8.4.279","article-title":"Is Montelukast Beneficial in Children with Atopic Dermatitis?","volume":"8","author":"Lee","year":"2016","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5114\/ada.2023.135759","article-title":"Comparative Efficacy of Combined Antihistamine and Montelukast Therapy in Adult Patients with Atopic Dermatitis","volume":"41","author":"Jamalyan","year":"2024","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/imt-2023-0037","article-title":"Upadacitinib for Moderate to Severe Atopic Dermatitis","volume":"15","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK Inhibitors in the Treatment of Atopic Dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_75","first-page":"1145","article-title":"Novel Insights into Atopic Dermatitis","volume":"151","author":"Billi","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/09546634.2020.1773385","article-title":"Off-Label Studies on Ruxolitinib in Dermatology: A Review","volume":"33","author":"Wu","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_77","first-page":"164","article-title":"Off-Label Studies on the Use of Ruxolitinib in Dermatology","volume":"32","author":"Tegtmeyer","year":"2021","journal-title":"Dermatol. Contact Atopic Occup. Drug."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/bjd\/ljac016","article-title":"Insights into Atopic Dermatitis Pathogenesis Lead to Newly Approved Systemic Therapies","volume":"188","author":"Trier","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.17218","article-title":"Nemolizumab is Associated with a Rapid Improvement in Atopic Dermatitis Signs and Symptoms: Subpopulation (EASI \u2265 16) Analysis of Randomized Phase 2B Study","volume":"35","author":"Silverberg","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","article-title":"Psoriasis in Children and Adolescents: Diagnosis, Management, and Comorbidities","volume":"17","author":"Bronckers","year":"2015","journal-title":"Paediatr. Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"122991","DOI":"10.1016\/j.lfs.2024.122991","article-title":"Advances in Psoriasis Research: From Pathogenesis to Therapeutics","volume":"355","author":"Sugumaran","year":"2024","journal-title":"Life Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) Project Team. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1346-8138.13186","article-title":"Psoriasis: Behind the Scenes","volume":"43","author":"Furue","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Kamiya, K., Kishimoto, M., Sugai, J., Komine, M., and Ohtsuki, M. (2019). Risk Factors for the Development of Psoriasis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184347"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The Correlation Between Disease Severity and Psychological Burden in Patients Treated with Biological Therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of Treatment Goals for Moderate to Severe Psoriasis: A European Consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Petit, R.G., Cano, A., Ortiz, A., Espina, M., Prat, J., Mu\u00f1oz, M., Severino, P., Souto, E.B., Garcia, M.L., and Pujol, M. (2021). Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094983"},{"key":"ref_91","first-page":"105","article-title":"Challenges in the Treatment of Psoriasis in Childhood","volume":"30","author":"Cvenkel","year":"2021","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat."},{"key":"ref_92","first-page":"1","article-title":"Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic","volume":"11","author":"Haulrig","year":"2021","journal-title":"Psoriasis Auckl. NZ"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1525-1470.2007.00341.x","article-title":"Tacrolimus Ointment is Effective for Psoriasis on the Face and Intertriginous Areas in Pediatric Patients","volume":"24","author":"Brune","year":"2007","journal-title":"Pediatr. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2310\/7750.2013.13059","article-title":"Efficacy of Topical Calcineurin Inhibitors in Psoriasis","volume":"18","author":"Wang","year":"2014","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40257-017-0294-9","article-title":"Pediatric Psoriasis","volume":"18","author":"Relvas","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Bro\u017cyna, A.A., Slominski, R.M., Nedoszytko, B., Zmijewski, M.A., and Slominski, A.T. (2022). Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158575"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2009.06.048","article-title":"Efficacy and Safety of Treatments for Childhood Psoriasis: A Systematic Literature Review","volume":"62","author":"Seyger","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2174\/0929867013371950","article-title":"Vitamin D Analogs: Mechanism of Action and Therapeutic Applications","volume":"8","author":"Nagpal","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"ref_99","first-page":"1","article-title":"Dithranol: A Review of the Mechanism of Action in the Treatment of Psoriasis Vulgaris","volume":"3","author":"Ruzicka","year":"1990","journal-title":"Skin Pharmacol. Off. J. Skin Pharmacol. Soc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/asj\/sjx005","article-title":"New Uses of AbobotulinumtoxinA in Aesthetics","volume":"37","author":"Schlessinger","year":"2017","journal-title":"Aesthet. Surg. J."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Martina, E., Diotallevi, F., Radi, G., Campanati, A., and Offidani, A. (2021). Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins, 13.","DOI":"10.3390\/toxins13020120"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Lewandowski, M., \u015awierczewska, Z., and Bara\u0144ska-Rybak, W. (2022). Off-Label Use of Botulinum Toxin in Dermatology-Current State of the Art. Molecules, 27.","DOI":"10.3390\/molecules27103143"},{"key":"ref_103","first-page":"1407","article-title":"Efficacy of Botulinum Neurotoxin Type A for Treating Recalcitrant Plaque Psoriasis","volume":"13","author":"Gilbert","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/jdv.12749","article-title":"Systemic Treatments in Pediatric Psoriasis: A Systematic Evidence-Based Update","volume":"29","author":"Mul","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kim, H.O., Kang, S.Y., Kim, J.C., Park, C.W., and Chung, B.Y. (2021). Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080940"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kanda, N., Hoashi, T., and Saeki, H. (2021). The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173880"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Diotallevi, F., Simonetti, O., Rizzetto, G., Molinelli, E., Radi, G., and Offidani, A. (2022). Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911128"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.det.2024.02.003","article-title":"Evolving Landscape of Biologic Therapy for Pediatric Psoriasis","volume":"42","author":"Do","year":"2024","journal-title":"Dermatol. Clin."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"103961","DOI":"10.1016\/j.amsu.2022.103961","article-title":"Two Cases of Erythrodermic Psoriasis Treated with Golimumab","volume":"78","author":"Kudsi","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/09546634.2021.1899111","article-title":"Successful treatment of paediatric generalized pustular psoriasis with secukinumab: A case series","volume":"33","author":"Albela","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1203475417721424","article-title":"Treatment of Moderate to Severe Psoriasis With High-Dose (450-mg) Secukinumab: Case Reports of Off-Label Use","volume":"22","author":"Beecker","year":"2018","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1203475419843118","article-title":"Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis","volume":"23","author":"Phung","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3109\/09546634.2015.1034070","article-title":"Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice","volume":"26","author":"Carrascosa","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: Results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/ced\/llad188","article-title":"Emerging role of topical Janus kinase inhibitors in dermatological disorders: A review","volume":"48","author":"Dogra","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/09546634.2019.1673877","article-title":"Off-label studies on tofacitinib in dermatology: A review","volume":"32","author":"Tegtmeyer","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"795","DOI":"10.36849\/jdd.7360","article-title":"Off-Label Use of Baricitinib in Dermatology","volume":"22","author":"Shah","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/JIR.S356316","article-title":"Application of Baricitinib in Dermatology","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","article-title":"A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19","volume":"39","author":"Bieber","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/1203475420909794","article-title":"Off-Label Therapeutic Potential of Crisaborole","volume":"24","author":"Makins","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_122","first-page":"22","article-title":"Updated Physician\u2019s Guide to the Off-label Uses of Oral Isotretinoin","volume":"7","author":"Nickle","year":"2014","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s13555-021-00524-w","article-title":"Use of H-1 Antihistamine in Dermatology: More than Itch and Urticaria Control: A Systematic Review","volume":"11","author":"Hsieh","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijwd.2020.01.009","article-title":"Sulfasalazine in dermatology: A lesser explored drug with broad therapeutic potential","volume":"6","author":"Mushtaq","year":"2020","journal-title":"Int. J. Women\u2019s Dermatol."},{"key":"ref_125","first-page":"235","article-title":"Low Dose Naltrexone in Dermatology","volume":"18","author":"Jaros","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","article-title":"Acne vulgaris","volume":"379","author":"Williams","year":"2012","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.det.2011.09.001","article-title":"Acne vulgaris: Pathogenesis, treatment, and needs assessment","volume":"30","author":"Dawson","year":"2012","journal-title":"Dermatol. Clin."},{"key":"ref_128","first-page":"1185","article-title":"Female type of adult acne: Physiological and psychological considerations and management","volume":"16","author":"Dreno","year":"2018","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.abd.2022.01.006","article-title":"Adult acne versus adolescent acne: A narrative review with a focus on epidemiology to treatment","volume":"98","author":"Kutlu","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Fox, L., Csongradi, C., Aucamp, M., du Plessis, J., and Gerber, M. (2016). Treatment Modalities for Acne. Molecules, 21.","DOI":"10.3390\/molecules21081063"},{"key":"ref_131","first-page":"e14438","article-title":"Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow-up, based on clinical studies","volume":"34","author":"Ghassemi","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/ijd.14761","article-title":"Update on the use of dapsone in dermatology","volume":"59","author":"Ghaoui","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/pde.12379","article-title":"Common use of prescription off-label acne therapy in children younger than 12 years old","volume":"31","author":"Parikh","year":"2014","journal-title":"Pediatr. Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/pde.12201","article-title":"Treatment of preadolescent acne in the United States: An analysis of nationally representative data","volume":"30","author":"Davis","year":"2013","journal-title":"Pediatr. Dermatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2147\/DDDT.S427530","article-title":"Oral Isotretinoin and Its Uses in Dermatology: A Review","volume":"17","author":"Paichitrojjana","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00403-020-02152-4","article-title":"Oral isotretinoin for the treatment of dermatologic conditions other than acne: A systematic review and discussion of future directions","volume":"313","author":"Chu","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Melnik, B.C. (2023). Acne Transcriptomics: Fundamentals of Acne Pathogenesis and Isotretinoin Treatment. Cells, 12.","DOI":"10.20944\/preprints202310.0472.v1"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_139","first-page":"e15311","article-title":"Low-dose oral isotretinoin for the treatment of adult patients with mild-to-moderate acne vulgaris: Systematic review and meta-analysis","volume":"35","author":"Almohssen","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0190-9622(84)80100-0","article-title":"Isotretinoin therapy for acne: Results of a multicenter dose-response study","volume":"10","author":"Strauss","year":"1984","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e13251","DOI":"10.1111\/dth.13251","article-title":"Low dose of isotretinoin: A comprehensive review","volume":"33","author":"Abdelmaksoud","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_142","first-page":"291","article-title":"Comparison of efficacy of fixed low-dose regimens (daily vs alternate day) of oral isotretinoin in mild to moderate acne vulgaris","volume":"25","author":"Niazi","year":"2015","journal-title":"Dermatol. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1365-4632.2012.05853.x","article-title":"Comparison of the efficacies of intermittent and continuous low-dose isotretinoin regimens in the treatment of moderate acne vulgaris","volume":"52","author":"Boyraz","year":"2013","journal-title":"Int. J. Dermatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jdv.12170","article-title":"Isotretinoin 5 mg daily for low-grade adult acne vulgaris--a placebo-controlled, randomized double-blind study","volume":"28","author":"Rademaker","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40257-020-00560-w","article-title":"Oral Antibiotics for Acne","volume":"22","author":"Patel","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40265-019-1053-4","article-title":"Sarecycline: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_147","first-page":"S5","article-title":"A Novel Antibiotic Just for Acne","volume":"19","author":"Kircik","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_148","first-page":"792","article-title":"To Acne and Beyond: A Review of Sarecycline\u2019s Off-Label Uses","volume":"23","author":"Vidal","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaad.2018.08.061","article-title":"Androgens in women: Hormone-modulating therapies for skin disease","volume":"80","author":"Azarchi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/ced.14340","article-title":"Spironolactone in dermatology: Uses in acne and beyond","volume":"45","author":"Searle","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"83334","DOI":"10.18632\/oncotarget.19833","article-title":"Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: Dienogest and drospirenone","volume":"8","author":"Regidor","year":"2017","journal-title":"Oncotarget"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"adv26002","DOI":"10.2340\/actadv.v104.26002","article-title":"Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study","volume":"104","author":"Nguyen","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"ref_153","first-page":"328","article-title":"Use of spironolactone in dermatology","volume":"8","author":"Rathnayake","year":"2010","journal-title":"Skinmed"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1542-2011.2011.00118.x","article-title":"Noncontraceptive uses of hormonal contraception","volume":"56","author":"King","year":"2011","journal-title":"J. Midwifery Women\u2019s Health"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.contraception.2008.10.010","article-title":"Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol\/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol\/2 mg cyproterone acetate","volume":"79","author":"Schellschmidt","year":"2009","journal-title":"Contraception"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humrep\/dem379","article-title":"Cyproterone acetate\/ethinyl estradiol for acne and hirsutism: Time to revise prescribing policy","volume":"23","author":"Franks","year":"2008","journal-title":"Hum. Reprod."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Minasi, A., Muscoli, C., Ilari, S., Mollace, V., Della Morte, D., and Bellia, A. (2022). Insulin resistance and acne: The role of metformin as alternative therapy in men. Pharmaceuticals, 16.","DOI":"10.3390\/ph16010027"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000512032","article-title":"Adalimumab in the management of isotretinoin-induced acne fulminans: Report of a case","volume":"7","author":"Marasca","year":"2021","journal-title":"Skin Appendage Disord."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/jamadermatol.2023.0269","article-title":"Role of tumor necrosis factor-\u03b1 inhibitors in the treatment and occurrence of acne: A systematic review","volume":"159","author":"Sandoval","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/dsu.12424","article-title":"Application of intense pulsed light in the treatment of dermatologic disease: A systematic review","volume":"40","author":"Wat","year":"2014","journal-title":"Dermatol. Surg."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaad.2009.09.057","article-title":"Photodynamic therapy for acne vulgaris: A critical review from basics to clinical practice: Part II. Understanding parameters for acne treatment with photodynamic therapy","volume":"63","author":"Sakamoto","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_162","first-page":"148","article-title":"A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: Inflammatory and aesthetic indications","volume":"12","author":"Rossi","year":"2013","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2014.08.028","article-title":"Rosacea: Part I. Introduction, categorization, histology, pathogenesis, and risk factors","volume":"72","author":"Two","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/12034754241229365","article-title":"Rosacea: Pathogenesis and therapeutic correlates","volume":"28","author":"Geng","year":"2024","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMcp042829","article-title":"Clinical practice. Rosacea","volume":"352","author":"Powell","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_167","first-page":"1","article-title":"Rosacea: An update in diagnosis, classification and management","volume":"26","author":"Kang","year":"2021","journal-title":"Skin Ther. Lett."},{"key":"ref_168","first-page":"CD003262","article-title":"Interventions for rosacea","volume":"2015","author":"Fedorowicz","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_169","first-page":"333","article-title":"A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks","volume":"11","author":"Chang","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.det.2017.11.010","article-title":"Medical management of facial redness in rosacea","volume":"36","author":"Cline","year":"2018","journal-title":"Dermatol. Clin."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/jdv.13801","article-title":"Efficacy and safety of permethrin 5% topical gel vs. placebo for rosacea: A double-blind randomized controlled clinical trial","volume":"30","author":"Raoufinejad","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_172","unstructured":"Nanda, J., Patel, P., and Juergens, A.L. (2024, November 26). Permethrin, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553150\/."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0190-9622(03)02157-1","article-title":"Tacrolimus effect on rosacea","volume":"50","author":"Bamford","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/jocd.14816","article-title":"Rosacea management: A comprehensive review","volume":"21","author":"Sharma","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14728214.2021.1887138","article-title":"Emerging topical drugs for the treatment of rosacea","volume":"26","author":"Nasca","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/jdv.20315","article-title":"Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis","volume":"39","author":"King","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.det.2017.11.001","article-title":"Rosacea pathogenesis","volume":"36","author":"Ahn","year":"2018","journal-title":"Dermatol. Clin."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e1361574","DOI":"10.1080\/19381980.2017.1361574","article-title":"Rosacea: Epidemiology, pathogenesis, and treatment","volume":"9","author":"Rainer","year":"2017","journal-title":"Dermato-Endocrinology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jid.2016.01.025","article-title":"A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea","volume":"136","author":"Sbidian","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_180","first-page":"505","article-title":"Systemic isotretinoin in the treatment of rosacea: Doxycycline- and placebo-controlled, randomized clinical study","volume":"8","author":"Gollnick","year":"2010","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00403-021-02277-0","article-title":"Role of botulinum toxin A in improving facial erythema and skin quality","volume":"314","author":"Hanna","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_182","first-page":"e51304","article-title":"The efficacy and safety of botulinum toxin A for the treatment of rosacea: A systematic review","volume":"15","author":"Alsaati","year":"2023","journal-title":"Cureus"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.3889\/oamjms.2019.784","article-title":"Botulinum toxin use in rosacea and facial flushing treatment","volume":"7","author":"Scala","year":"2019","journal-title":"Open Access Maced. J. Med. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2376\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:06:02Z","timestamp":1760029562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":183,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14072376"],"URL":"https:\/\/doi.org\/10.3390\/jcm14072376","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,30]]}}}